Verdelli C, Avagliano L, Creo P, Guarnieri V, Scillitani A, Vicentini L, Steffano G B, Beretta E, Soldati L, Costa E, Spada A, Bulfamante G P, Corbetta S
Laboratory of Molecular BiologyIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalyDepartment of Human PathologySan Paolo Hospital, University of Milan, Milan, ItalyLaboratory of Stem Cells for Tissue EngineeringIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalyMedical GeneticsEndocrinology UnitIRCCS Hospital Casa Sollievo Sofferenza, San Giovanni Rotondo, Foggia, ItalyEndocrine SurgeryIRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, ItalySurgery UnitIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalySurgery UnitIRCCS Ospedale San Raffaele, Milan, ItalyDepartment of Health SciencesEndocrinology and Diabetology UnitDepartment of Clinical and Community Sciences, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, ItalyEndocrinology and Diabetology UnitDepartment of Biomedical Sciences for Health, IRCCS Policlinico San Donato, University of Milan, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy.
Laboratory of Molecular BiologyIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalyDepartment of Human PathologySan Paolo Hospital, University of Milan, Milan, ItalyLaboratory of Stem Cells for Tissue EngineeringIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalyMedical GeneticsEndocrinology UnitIRCCS Hospital Casa Sollievo Sofferenza, San Giovanni Rotondo, Foggia, ItalyEndocrine SurgeryIRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, ItalySurgery UnitIRCCS Policlinico San Donato, San Donato Milanese, Milan, ItalySurgery UnitIRCCS Ospedale San Raffaele, Milan, ItalyDepartment of Health SciencesEndocrinology and Diabetology UnitDepartment of Clinical and Community Sciences, IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, ItalyEndocrinology and Diabetology UnitDepartment of Biomedical Sciences for Health, IRCCS Policlinico San Donato, University of Milan, Via Morandi 30, 20097 San Donato Milanese, Milan, Italy
Endocr Relat Cancer. 2015 Feb;22(1):87-98. doi: 10.1530/ERC-14-0161. Epub 2014 Dec 16.
Components of the tumour microenvironment initiate and promote cancer development. In this study, we investigated the stromal component of parathyroid neoplasia. Immunohistochemistry for alpha-smooth muscle actin (α-SMA) showed an abundant periacinar distribution of α-SMA(+) cells in normal parathyroid glands (n=3). This pattern was progressively lost in parathyroid adenomas (PAds; n=6) where α-SMA(+)cells were found to surround new microvessels, as observed in foetal parathyroid glands (n=2). Moreover, in atypical adenomas (n=5) and carcinomas (n=4), α-SMA(+) cells disappeared from the parenchyma and accumulated in the capsula and fibrous bands. At variance with normal glands, parathyroid tumours (n=37) expressed high levels of fibroblast-activation protein (FAP) transcripts, a marker of tumour-associated fibroblasts. We analysed the ability of PAd-derived cells to activate fibroblasts using human bone-marrow mesenchymal stem cells (hBM-MSCs). PAd-derived cells induced a significant increase in FAP and vascular endothelial growth factor A (VEGFA) mRNA levels in co-cultured hBM-MSCs. Furthermore, the role of the calcium-sensing receptor (CASR) and of the CXCL12/CXCR4 pathway in the PAd-induced activation of hBM-MSCs was investigated. Treatment of co-cultures of hBM-MSCs and PAd-derived cells with the CXCR4 inhibitor AMD3100 reduced the stimulated VEGFA levels, while CASR activation by the R568 agonist was ineffective. PAd-derived cells co-expressing parathyroid hormone (PTH)/CXCR4 and PTH/CXCL12 were identified by FACS, suggesting a paracrine/autocrine signalling. Finally, CXCR4 blockade by AMD3100 reduced PTH gene expression levels in PAd-derived cells. In conclusion, i) PAd-derived cells activated cells of mesenchymal origin; ii) PAd-associated fibroblasts were involved in tumuor neoangiogenesis and iii) CXCL12/CXCR4 pathway was expressed and active in PAd cells, likely contributing to parathyroid tumour neoangiogenesis and PTH synthesis modulation.
肿瘤微环境的组成部分启动并促进癌症发展。在本研究中,我们调查了甲状旁腺肿瘤的基质成分。α平滑肌肌动蛋白(α-SMA)免疫组化显示,正常甲状旁腺(n=3)中α-SMA(+)细胞在腺泡周围大量分布。在甲状旁腺腺瘤(PAds;n=6)中,这种模式逐渐消失,在甲状旁腺腺瘤中发现α-SMA(+)细胞围绕新的微血管,这与胎儿甲状旁腺(n=2)中观察到的情况相同。此外,在非典型腺瘤(n=5)和癌(n=4)中,α-SMA(+)细胞从实质中消失,并积聚在包膜和纤维带中。与正常腺体不同,甲状旁腺肿瘤(n=37)表达高水平的成纤维细胞激活蛋白(FAP)转录本,这是肿瘤相关成纤维细胞的标志物。我们使用人骨髓间充质干细胞(hBM-MSCs)分析了PAd来源细胞激活成纤维细胞的能力。PAd来源细胞在共培养的hBM-MSCs中诱导FAP和血管内皮生长因子A(VEGFA)mRNA水平显著增加。此外,研究了钙敏感受体(CASR)和CXCL12/CXCR4途径在PAd诱导的hBM-MSCs激活中的作用。用CXCR4抑制剂AMD3100处理hBM-MSCs和PAd来源细胞的共培养物可降低刺激后的VEGFA水平,而R568激动剂激活CASR则无效。通过荧光激活细胞分选术(FACS)鉴定出共表达甲状旁腺激素(PTH)/CXCR4和PTH/CXCL12的PAd来源细胞,提示存在旁分泌/自分泌信号传导。最后,AMD3100阻断CXCR4可降低PAd来源细胞中PTH基因表达水平。总之,i)PAd来源细胞激活间充质来源的细胞;ii)PAd相关成纤维细胞参与肿瘤新生血管形成;iii)CXCL12/CXCR4途径在PAd细胞中表达并具有活性,可能有助于甲状旁腺肿瘤新生血管形成和PTH合成调节。